Indian Institute of Technologies Kanpur licenses gene therapy technologies for hereditary illnesses

(Image Credit: AdobeStock/vladimircaribb)

The Indian Institute of Technologies (IIT) Kanpur announced in a press release the institute has licensed a gene therapy technologies to Reliance Life Sciences Pvt. Ltd.

This marks the initial time in history a gene therapy associated technologies has been created and transferred from an academic institution to a firm in India. The gene therapy technologies from IIT Kanpur will be additional created as an Indigenous Solution by Reliance Life Sciences according to the institute.1

According to the press release from the institute, the technologies licensing agreement was formally signed amongst IIT Kanpur and Reliance Life Sciences Pvt. Ltd. at a MoU exchange ceremony in the presence of a number of dignitaries. Some of these dignitaries incorporated Abhay Karandikar, PhD, Director of IIT Kanpur, and K. V. Subramaniam, MBA, PhD, Licensee &amp President of Reliance Life Sciences.

“We are pleased to have the chance to operate with IIT Kanpur to additional create this essential technologies,” mentioned Subramaniam in the press release. “Reliance Life Sciences is a study-driven, health-related biotechnology firm and we are thrilled to collaborate and take forward this revolutionary technologies to commercialization.”

The patented technologies was created by Jayandharan Giridhara Rao, PhD, and Shubham Maurya, PhD, from the Division of Biological Sciences and Bioengineering (BSBE), IIT Kanpur and “modifies the gene of an organism to treat a hereditary disorder.”

IIT Kanpur states the “technology modifies a place to optimize its potential to provide genes to the impacted cells and enhance its effectiveness,” and that the technologies has the potential to “improve gene therapy for lots of hereditary illnesses, specially inherited eye illnesses.”

“IIT Kanpur is committed to establishing impactful technologies in the field of healthcare, and we are delighted to see the licensing of this gene therapy technologies to Reliance Life Sciences,” mentioned Karandikar. “Gene therapy making use of viral vectors has not too long ago emerged as a potent tool in the field of molecular medicine. We think that this technologies holds excellent guarantee for treating a wide variety of hereditary eye illnesses which includes Leber congenital amaurosis, an eye disorder that is present from birth and Retinitis pigmentosa, a illness causing progressive sustained vision loss.”

References: